

# C4X Discovery Holdings PLC

01:02 22 Jun 2020

## C4X Discovery on hunt for next partnership deal

### What C4X does

C4X Discovery Holdings plc's (LON:C4XD) stated aim is to become the world's most productive drug discovery engine.

To achieve this goal it is using cutting-edge technologies and expertise to efficiently deliver small-molecule (pharmaceutical) medicines.

It has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental data.

This enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.

**Price:** 18

**Market Cap:** £21.46 m

### 1 Year Share Price Graph



August 2019 February 2020 August 2020

### Share Information

**Code:** C4XD

**Listing:** AIM

52 week	High	Low
	46.3286	7


**Sector:** Medical technology & services

**Website:** [www.c4xdiscovery.com](http://www.c4xdiscovery.com)

### Company Synopsis:

*C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)



Unlike many drug companies, it looks to find partners at the pre-clinical phase, allowing big pharma to fund expensive human trials.

It successfully out-licensed its programme for addictive disorders to Indivior, receiving an upfront £7.7m (US\$10m) and milestones of £227m (US\$294m).


It is working on potential treatments for Parkinson's, Alzheimer's and inflammatory bowel disorders and it has numerous collaboration deals.

Below is the company's drug pipeline

C4X is driving 11 active<sup>1</sup> discovery programmes with 3 in late-stage discovery



C4X has built a well-balanced portfolio across strategic and opportunistic<sup>2</sup> TAs



## How it is doing

In June chief executive Clive Dix was appointed as a member and deputy chair of the steering board of the UK Vaccine Taskforce.

In May, the AIM-listed firm raised £1.6m through an oversubscribed placing at 15p a throw to strengthen its balance sheet as its partnering and strategic collaborations progress and will boost working capital during the progression of its

pipeline portfolio. C4X said the new funds should provide it with at least twelve months working capital.

In April C4X said its closely-watched NRF-2 activator programme for sickle cell disease and pulmonary arterial hypertension was down to a short-list of three molecules.

FTSE 250-listed drug group Indivior was preparing to take C4X's treatment for opioid use disorder into the clinic as part of a deal worth US\$294m. Phase I and II studies will receive financial backing from the National Institutes of Health in the US.

At the same time, its high-value, early-stage drug candidate designed to inhibit interleukin-17, showed early encouraging signs in inflammation.

The six months to January ended with cash and equivalents of £5.5m, while the value of its intellectual property was £10.3m. Investment in research and development during the six months to January 31 was £3.6m, down £1.3m from a year ago. As would be expected from a company heavily focused on research, it was loss-making - to the tune of £4.89m at the operating level, down from £6.26m a year earlier.

## What the boss says: Clive Dix, chief executive

"We would like to thank Polar Capital and our other new and existing investors for their active support of C4XD and continued belief in our vision."

"It is encouraging to see investor understanding of the ongoing long-term contribution of the life sciences industry and the value of innovative, early-stage drug discovery amidst the uncertainties generated by the COVID-19 pandemic."

"These additional resources will support our continuing scientific progress and commercial discussions across our portfolio."

## Inflexion points

- **Clinical trial for the Orexin-1 programme with Indivior**
- **A partner for the NRF-2 activator programme with the company seeing commercial interest**
- **Partners for other projects under development**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).